Comparator treatment | 12Â weeks 12 studies |
---|---|
RR (95Â % Crl) (vs. ivermectin 1Â % cream QD) | |
 Azelaic acid 15 % gel QD | 1.33 (0.99 to 2.20) |
 Azelaic acid 15 % gel BID | 1.25 (1.14 to 1.37) |
 Metronidazole 0.75 % cream BID | 1.17 (1.08 to 1.29) |
 Metronidazole 1 % gel QD | 1.18 (0.98 to 1.56) |
 Silica encapsulated benzoyl peroxide 1 % gel QD | 1.09 (0.86 to 1.78) |
 Silica encapsulated benzoyl peroxide 5 % gel QD | 0.94 (0.81 to 1.29) |
 Vehicle | 1.56 (1.46 to 1.65) |
NNT (95Â % Crl) (vs. vehicle) | |
 Azelaic acid 15 % gel QD | 7 (−120 to 120) |
 Azelaic acid 15 % gel BID | 9 (6 to 14) |
 Metronidazole 0.75 % cream BID | 6 (4 to 13) |
 Metronidazole 1 % gel QD | 6 (3 to 41) |
 Silica encapsulated benzoyl peroxide 1 % gel QD | 4 (−31 to 44) |
 Silica encapsulated benzoyl peroxide 5 % gel QD | 3 (2 to 9) |
 Ivermectin 1 % cream QD | 3 (3 to 4) |